Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-04-19
2011-04-19
Oh, Taylor Victor (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C564S123000
Reexamination Certificate
active
07928145
ABSTRACT:
Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
REFERENCES:
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5536727 (1996-07-01), Witzel et al.
patent: 5610162 (1997-03-01), Witzel et al.
patent: 5776888 (1998-07-01), Leone-Bay
patent: 5783593 (1998-07-01), Baker et al.
patent: 5972978 (1999-10-01), Anderson et al.
patent: 6034096 (2000-03-01), Bertolini et al.
patent: 6045829 (2000-04-01), Liversidge et al.
patent: 6174905 (2001-01-01), Suzuki et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6743807 (2004-06-01), Duan et al.
patent: 6858626 (2005-02-01), Xue et al.
patent: 6984648 (2006-01-01), Lu et al.
patent: 7183268 (2007-02-01), Zemlicka et al.
patent: 7235689 (2007-06-01), Pinori et al.
patent: 7410988 (2008-08-01), Dickson, Jr. et al.
patent: 2003/0091623 (2003-05-01), Cumming et al.
patent: 2003/0225054 (2003-12-01), Duan
patent: 2004/0092598 (2004-05-01), Watkins et al.
patent: 2009/0137679 (2009-05-01), Chen
patent: 974576 (2001-01-01), None
patent: 01/16106 (2001-03-01), None
patent: 01/34131 (2001-05-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/70675 (2001-09-01), None
patent: 02/26696 (2002-04-01), None
patent: 02/074298 (2002-09-01), None
patent: 03/013493 (2003-02-01), None
patent: WO03070691 (2003-08-01), None
patent: 2005/055928 (2005-06-01), None
Jung Manfred, Inhibitors of Histone Deacetylase as New Antiucancer Agents, current Medicinal Chemistry 2001, 8, 1505-1511.
International Search Report and Written Opinion from PCT/US2004/40211, mailed Jul. 25, 2005 (4 pages).
Taunton et al., “A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p,” Science, 272, 408-411, Apr. 19, 1996.
Yoshida et al., “Potent and Specific Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A,” J. Biol. Chem., 265, 17174-17179, Oct. 5, 1990.
Office action from U.S. Appl. No. 12/361,626 dated Sep. 23, 2009.
Amendment from U.S. Appl. No. 12/361,626 dated Jan. 25, 2010.
Supplemental Amendment from U.S. Appl. No. 12/361,626 dated Feb. 24, 2010.
Office action from U.S. Appl. No. 12/361,626 dated May 28, 2010.
European Search report dated Jun. 1, 2010 from EP Application No. 04812666.
Finnin et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors”, Nature, 401, 188-193, 1999.
Fuino, et al, “Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuumab, taxotere, gemcitabine, and epothilone B”, Mol Cancer Ther, 2, 971-984, 2003.
Furumai et al., “Potent histone deacetylase inhibitors build from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin”, Proc Natl Acad Sci USA, 98: 87-92, 2001.
Grozinger et al. “Deacetylase enzymes: biological functions and the use of small-molecule inhibitors”, Chem Biol 9: 3-16, 2002.
Johnstone, “Histone-deacetylase inhibitors: novel drugs for the treatment of cancer”, Nat Rev Drug Discov, 1: 287-299, 2002.
Kijima et al., “Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase”, J Biol Chem, 268, 22429-22435, 1993.
Kramer et al. “Histone deacetylase as a therapeutic target”, Trends Endocrinol Metab, 12: 294-300, 2001.
Lea et al., “Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase”, Anticancer Res. 15, 879-883, 1995.
Lu, et al., “Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors”, J Med Chem, 47, 467-474, 2004.
Marks et al. “Histone deacetylases and cancer: causes and therapies”, Nat. Rev. Cancer 1: 194-202, 2001.
Nakajima et al., “FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor”, Exp Cell Res 241, 126-133, 1998.
Remiszewski et al, “Inhibitors of human histone deacetylase: synthesis and enzyme and cellular ativity of straight chain hydroxamates” J Med Chem, 45, 753-757, 2002.
Richon et al., “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases”, Proc Natl Acad Sci USA 95 3003-3007, 1998.
Shute et al., “Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides”, J Med Chem 30, 71-78, 1987.
Sternson et al., “Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin”, Org. Lett. 3, pp. 4239-4242 (2001).
Vanommeslaeghe et al., Ab initio study of the binding of Trichostatin A (TSA) in the active site of histone deacetylase like protein (HDLP), Org Biomol Chem, 1, 2951-2957, 2003.
Han et al., “Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin”, Cancer Res, 60, 6068-6074, 2000.
Jung et al., “Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation”, J Med Chem 42, 4669-4679, 1999.
Kim et al., “Inhibition of histone deacetylase ncreases cytotoxicity to anticancer drugs targeting DNA”, Cancer Res 63, 7291-7300, 2003.
Kim et al., “Synthesis and Biological Evolution of 3-(4-Substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors”, J of Medicinal Chemistry, American Chemical Society, vol. 46, No. 26, Jan. 1, 2003, pp. 5745-5751.
Kraker et al., “Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma”, Mol Cancer Ther, 2, 401-408, 2003.
Lu et al., “Efficacy of a Novel Histone Deacetylase Inhibitor in Murine Models of Hepatocellular Carcinoma”, Hepatology, pp. 1119-1130, Oct. 2007.
Lucas et al., “The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells”, Leukemia, 18, 1207-1214, 2004.
Maeda et al., “Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities”, Bioorganic & Medicinal Chemistry, vol. 12, No. 16, pp. 4351-4360, Juy 1, 2004.
Marks et al. “Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells”, J Natl Cancer Inst, 92: 1210-1216, 2000.
Miller, et al., “Histone deacetylase inhibitors”, J Med Chem 46, 5097-5116, 2003.
Piekarz, et al., “T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance”, Blood, 103, 4636-4643, 2004.
Yang et al., “A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer”, Neoplasia, vol. 11, No. 6, Jun. 2009, pp. 552-563.
Lucas et al., “The novel deacetylase inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo”, PLOS ONE, vol. 5, issue 6, pp. 1-10, Jun. 2010.
Chen Ching-Shih
Qiang Lu
Calfee Halter & Griswold LLP
Oh Taylor Victor
The Ohio State University Research Foundation
LandOfFree
Zn 2+ -chelating motif-tethered short-chain fatty acids as a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Zn 2+ -chelating motif-tethered short-chain fatty acids as a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Zn 2+ -chelating motif-tethered short-chain fatty acids as a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676657